Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Selective factor Xa inhibitor assessed in experimental model of tumor-induced DIC

Jan. 13, 2000

Phase III data reported for rhATIII

Jan. 12, 2000

New thrombin inhibitors presented by Merck & Co. research group

Jan. 6, 2000

Condensed heterocycles and ester prodrugs as potent antiplatelet, antithrombotic agents

Jan. 5, 2000

Merck describes thrombin-specific anticoagulants

Jan. 3, 2000

New approach to inhibiting thrombin-induced neuronal cell death

Dec. 29, 1999

Update on preclinical and clinical testing of R.W. Johnson's fibrinogen antagonist

Dec. 27, 1999

Recently issued patent covers Berlex's new anticoagulants

Dec. 23, 1999

Selective, orally active factor Xa inhibitors designed by JT scientists

Dec. 22, 1999

Meiji Seika presents heterocyclic inhibitors of platelet aggregation

Dec. 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...